TABLE 1.
Viral clearance in IFN-γ KO, β2KO, and IFN-γKO/β2KO mice
| Expt (inoculum)a | Genotypeb | Mean log10 PFU/gram of tissue ± SD (no. of mice with detectable virus/total no. of mice)c in:
|
No. of mice surviving to day 10/total no. of mice | |||
|---|---|---|---|---|---|---|
| Feet (day 8) | Spinal ganglia | Feet (day 10) | Spinal ganglia | |||
| 1 (5 × 105 PFU) | IFN-γKO/β2KO | 7.7 ± 0.0 (2/2) | 5.4 ± 0.2 (2/2) | 6.2 ± 1.4 (2/2) | 3.9 ± 0.5 (2/2) | 2/11 |
| IFN-γKO/β2het | 4.8 ± 2.3 (4/4) | 2.6 ± 1.9 (2/4) | 4.1 ± 2.1 (4/5) | 2.4 ± 1.3 (3/5) | 5/8 | |
| IFN-γhet/β2KO | 6.0 ± 0.3 (2/2) | 4.1 ± 0.5 (2/2) | 5.7 ± 0.7 (2/2) | 2.7 ± 2.4 (1/2) | 2/6 | |
| IFN-γhet/β2het | 3.3 ± 2.8 (1/3) | 2.0 ± 2.0 (1/4) | <1 (0/5)d | <1 (0/5)e | 6/7 | |
| 2 (106 PFU) | IFN-γKO/β2KO | 7.9 ± 0.0 (2/2) | 6.3 ± 0.2 (2/2) | 7.5 (1/1) | 4.8 (1/1) | 1/4 |
| IFN-γKO/β2het | 7.0 ± 1.0 (3/3) | 5.1 ± 0.6 (3/3) | 6.1 ± 0.9 (2/2) | 3.5 ± 0.0 (2/2) | 2/4 | |
| IFN-γhet/β2KO | 6.4 ± 0.8 (5/5) | 5.7 ± 1.0 (5/5) | 6.7 ± 0.1 (2/2) | 2.7 ± 0.4 (2/2) | 2/4 | |
| IFN-γhet/β2het | 6.7 ± 0.7 (4/4) | 3.2 ± 2.6 (2/4) | 4.9 ± 2.0 (2/2) | 2.4 ± 1.0 (1/2) | 2/4 | |
a
Amount of virus inoculated into each footpad.
b
IFN-γhet, IFN-γ heterozygous; β2het, β2 heterozygous.
c
The limit of detectability was 1 log10; mice with undetectable virus were assigned a value of 1 log10/gram of tissue for purposes of analysis.
d
P < 0.001 with IFN-γ heterozygous/β2 heterozygous mice versus IFN-γKO/β2KO mice and IFN-γ heterozygous/β2KO mice. P = 0.01 with IFN-γ heterozygous/β2 heterozygous mice versus IFN-γKO/β2 heterozygous mice.
e
P < 0.001 with IFN-γ heterozygous/β2 heterozygous mice versus IFN-γKO/β2KO mice. P = 0.04 with IFN-γ heterozygous/β2 heterozygous mice versus IFN-γKO/β2 heterozygous mice.